Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 4/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291175 | 0.85 | ALDH1A1 (0.45) | NR3C2RXFP1PGRNR3C1MMP12 | |
| SCHEMBL4289205 | 0.84 | NR3C2 (0.45) | NR3C2RXFP1PGRNR3C1MMP12 | |
| SCHEMBL4290971 | 0.84 | ALDH1A1 (0.41) | NR3C2RXFP1MMP12MAPTALDH1A1 | |
| SCHEMBL1730697 | 0.81 | ALDH1A1 (0.39) | NR3C2RXFP1MAPTALDH1A1PDE3B | |
| SCHEMBL4297177 | 0.81 | MAPT (0.46) | NR3C2RXFP1MAPTALDH1A1PDE3B | |
| SCHEMBL9909523 | 0.80 | NR3C2 (0.47) | NR3C2PGRNR3C1MMP12PDE3B | |
| SCHEMBL4102418 | 0.79 | PDE3B (0.56) | NR3C2PGRNR3C1MMP12MAPT | |
| SCHEMBL4295975 | 0.78 | NR3C2 (0.43) | NR3C2PGRNR3C1MAPTALDH1A1 | |
| SCHEMBL4299788 | 0.77 | NR3C2 (0.42) | NR3C2PGRNR3C1MAPTALDH1A1 | |
| SCHEMBL8082246 | 0.76 | PGR (0.46) | NR3C2PGRNR3C1MMP12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1971596-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | NR3C2 1/4885RXFP1 381/4885PGR 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.